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Background: An imbalance in the ratio of arachidonic acid and docosahexaenoic acid (DHA) was found in cystic fibrosis (CF) affected
tissues and was suggested to promote inflammation. Several studies have shown that the long chain n-3 fatty acids reduced inflammatory
activity while others have highlighted prooxidant activity of DHA at high concentrations. The aim of our study was to evaluate the effects
of an intravenous fish-oil emulsion enriched with n-3 FA in patients with CF on plasma and platelet FA composition and peroxidation
markers.
Methods: 13 patients with CF received one IV emulsion per week of 2 mL/kg fish-oil n-3 emulsion for 12 weeks.
Results: There was a significant increase in 20:5 n-3 and 22:6 n-3 platelet FA composition, no variation in 20:4 n-6, a decrease in n-9. There
was no variation in plasma FA composition. Specific urinary markers of lipid peroxidation derived from n-3 and n-6 showed a very high level
before infusion compared with usual values in healthy subjects which was not affected by treatment. A significant weight loss and a decrease
in reduced glutathione were observed in adult patients.
Conclusions: The intravenous administration of n-3 FA in CF patients induced a significant modification in platelet FA composition but no
modification of oxidative markers. However, the weight loss and the decreased level in reduced glutathione observed in adult patients may
suggest a potential deleterious activity for some patients. Further studies are necessary to determine the optimal dose and route for long chain
FA administration required to reach a potential beneficial effect.
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Several studies have suggested a link between the genetic
defect leading to Cystic Fibrosis (CF) and abnormal polyun-
saturated fatty acid (FA) metabolism [1,2]. An intrinsic
imbalance in the ratio of membrane fatty acids with aned by Elsevier B.V. All rights reserved.
Table 1
Main clinical characteristics of patients before administration of treatment
Patient no Age
(year)
Height
(cm)
Weight
(kg)
BMI
(kg/m2)
FEV1
(%)
1 7 126 24.5 15.54 94
2 7 120 22.2 15.3 88
3 8 132 27.3 15.67 64
4 8 128 27.2 16.7 95
5 10 140 28.5 14.4 77
6 15 157 52.2 21.2 71
Median 8 130 27.3 15.4 8382
(min–max) (7–15) (120–157) (22.2–52.2) (14.4–21.2) (64–95)
7 32 173 62.7 21 44
8 23 159 45 17.8 45
9 26 164 48 17.8 76
10 37 167 56 20.1 49
11 35 150 45 20 41
12 19 166 50 19.4 69
13 25 167 53.5 17.9 33
Median 26 166 50 19.4 45
(min–max) (19–37) (150–173) (45–62.7) (17.8–21) (33–76)
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of docosahexaenoic acid (C22:6 n-3; DHA) was found in
CFTR-expressing tissues [3] suggesting it may promote
inflammation. A defective regulation of FA metabolism,
with defective regulation and increased turnover of AA
(a pro-inflammatory agent) and elevated production of
eicosanoids [4], or an alteration of FA incorporation in
membrane cells [5] have been suggested. The link between
FA membrane profile and CF phenotype has been suggested
by (i) the CF phenotype of EFA-deficient animals [6], (ii)
the correction of some pathological manifestations in CF
mice concomitantly with the correction of membrane lipid
imbalance [3], and (iii) the link between CF genotype and
essential FA plasma and mucosal profiles in CF patients
[1,2].
Some authors have suggested a link between the FA
profile and the high levels of inflammation and oxidative
stress, particularly lipid peroxidation, observed in CF both at
plasmatic and airway levels [7,8]. Previous studies have
evaluated the effect of fatty acid supplementation in CF
patients with different doses and ways of administration and
various evaluated criteria [9–12], showing either little or no
clinical beneficial effect but some biological anti inflamma-
tory effects like decrease in LTB4/LTB5 ratio [13].
Eicosapentaenoic acid (C20:5 n-3 EPA) and DHA have
demonstrated beneficial effects in some inflammatory and
vascular diseases [14]. They belong, however, to the n-3
family of long chain polyunsaturated fatty acids, and DHA is
particularly highly oxidizable owing to the presence of its six
double bonds in the 22-carbon fatty acyl chain, suggesting
that DHA may also increase the peroxidative process which
is already present in cystic fibrosis. A previous study in
healthy subjects showed that high-dose and long-time treat-
ment with n-3 FA increased the susceptibility of red blood
cell membranes to lipid peroxidation [15]. A recent study
highlighted pro- or antioxidant activities of DHA at high and
low concentrations respectively, on human blood platelets
in vitro [16].
We based the rationale of our study on the hypothesis that
long chain polyunsaturated n-3 supplementation may have
potential conflicting effects on oxidative status in CF
patients; this justifies to assess in a preliminary pilot study
their absence of biological criteria for potential deleterious
effects. This caution seems necessary before further clinical
trials to demonstrate potential clinical improvement. We
chose the intravenous route because of potential lipids
malabsorption in CF patients.
Thus, the aim of our preliminary study was (i) to evaluate
the effects of an intravenous fish-oil emulsion enriched with
n-3 FA on platelet and plasma composition in order to
observe a potential modification at both plasmatic and mem-
brane cell level, which is an indirect sign of n-3 membrane
incorporation; (ii) to survey some peroxidation and antiox-
idant markers in order to check the biological safety of this
administration in patients with CF. A significant membrane
incorporation of n-3 FA and the absence of clinical andbiological toxic effects are useful and essential criteria for
further randomized clinical trials.
2. Patients and methods
2.1. Patients and study design
Thirteen patients with a well established diagnosis of CF
attending the pediatric or the adult cystic fibrosis centers in
Lyon, France, were included in the study. The study was
approved by the ethics committee of the university hospital
of Lyon. Informed consent was obtained from patients older
than 18 years and from their parents when younger.
The inclusion criteria were: patients between 5 and
40 years old, with pancreatic insufficiency and stable pulmo-
nary disease. Exclusion criteria were cirrhosis, transplanted
patients or those waiting for transplantation, and patients
treated with nocturnal enteral nutrition. All patients received
pancreatic enzymes and adapted supplementation with
retinol and tocopherol depending on annual plasmatic level
dosing.
The clinical conditions are summarized in Table 1.
All subjects received a weekly intravenous administration
of 2 mL per kg body weight of an enriched fish-oil emulsion
(Omegavenous®. Fresenius Kabi) for 12 weeks. The
Omegavenous® composition for 100 ml was 10 g of fish-
oil, including 1.25 to 2.82 g of EPA, 1.44 to 3.09 g of DHA,
0.1 to 0.7 g of linoleic acid (C18:2 n-6), less than 0.2 g of
alpha linolenic acid (C18:3 n-3), and 0.1 to 0.4 g of AA. Each
patient received a two-week course of antibiotic treatment
according to their sputum culture results and usual antibiotic
regimen, before and at the end of the 12-week treatment.
Each of the two evaluations was performed in fasted subjects,
after the end of the antibiotic course in order to minimize the
effects of bronchial infection on the evaluated parameters,
particularly the inflammatory and oxidative markers. The
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before the first lipid infusion, the second evaluation was
done one week after the last infusion at the end of the
second antibiotic course. Each patient was his own control
for each parameter measured before and after treatment,
and, as the study was a preliminary observational one con-
cerning only biological criteria, no control group was
considered. We included an empirical number of twelve
patients – six adults and six children– in order to have
experimental biological analysis in both children and adult
patients. One more adult patient was included after one of
them retired.
The evaluated clinical parameters were: weight, height
and body mass index (BMI: weight (kg)/height (m)2), FEV1
and FVC expressed as a percentage of predicted value,
sputum colonization. A sweat chloride concentration was
also measured by the Gibson and Cook method before and
after treatment.
2.2. Laboratory tests
2.2.1. Platelet lipid fatty acid composition
Platelet preparation: Blood samples were collected in
tubes containing acid–citrate–dextrose (ACD; 0.8% citric
acid, 2.2% sodium citrate, and 2.45% dextrose, 6:1 vol/vol).
Platelet-rich plasma was prepared as previously described
[17]. Briefly, platelet-rich plasma obtained by centrifugation
of the blood at 100 g for 15 min was acidified to pH 6.4 with
citric acid and centrifuged at 900 g for 20 min. The resulting
platelet pellet was resuspended in a Tyrode-HEPES buffer
solution (in mmol/L: 137 NaCl, 2.6 KCl, 11.9 NaHCO3, 0.46
NaH2 PO4, 1 MgCl2 and 5.5 dextrose, pH 7.35).
Total lipids were transmethylated for 90 min at 100 °C
with 5% concentrated sulfuric acid in methanol [18]. The
resulting fatty acid methyl esters and fatty aldehyde dimethyl
acetals (DMA) were analyzed by gas-liquid chromatography
(GC) using a Hewlett Packard (HP 6890 series) chromato-
graph equipped with an SP 2380 capillary column
(30 m×0.32 mm, Supelco, Bellefonte, PA, USA).
2.2.2. Platelet glutathione peroxidase activities
Measurement of cytosolic glutathione peroxidase (cGPx
or GPx-1) activity was carried out according to the method
described by Paglia and Valentine [19] as modified by
Chaudière and Gérard [20].
Phospholipid hydroperoxide glutathione peroxidase
(PHGPx or GPx-4) activity was assayed by the procedure
of Roveri et al. [21].
2.2.3. Plasma FA analysis in phospholipids and cholesterol
ester fractions
Lipids were extracted by chloroform/methanol (1:1, v/v).
The extract was washed by saline solution to remove pro-
teins. The chloroform phase was concentrated under a stream
of nitrogen and taken up in chloroform/methanol. The lipid
classes were separated by thin-layer chromatography onsilicagel plates (Merck 5721) using petroleum ether–ethylic
ether–acetic acid as developing solvent. The plates were
sprayed with bromophenol blue, and individual bands of
phospholipids and cholesteryl esters were scraped off into
separate tubes. The phospholipid fraction was saponified and
transmethylated with sodium methylate, and the cholesteryl
ester fraction was methylated with sulphuric acid and dehy-
drated methanol. The methyl esters of each fraction were
removed by hexane and analyzed by gas liquid chromatog-
raphy on a Fison GC-8000 gas chromatograph (Thermo
Separation Products, Les Ulis, France) equipped with a CP-
SIL fused silica capillary column (25 m×0.25 mm internal
diameter) coated with 100% cyanopropyl siloxane 88 phase
0.2 μm (Chrompack Les Ulis, France), helium as carrier gas,
and a split ratio 1:20.
Initial temperature was 120 °C for 1 min then temperature
programming was as follows: +20°C/min until 165 °C
maintained for 20 min, +1 °C/min until 210 °C maintained
for 1 min, +10 °C/min until 250 °C maintained for 5 min.
Identification of the individual methyl ester components was
made by frequent comparison with authentic standards and
with their retention times. The results were expressed as a
percentage of the total area of all fatty acid peaks in each
lipid fraction, and quantified (mg/l) with the internal
Standard added at the beginning of analysis.
2.2.4. Antioxidant and oxidative markers
Methods for measuring plasma vitamin A and E,
carotenoids, true malonedialdehyde (MDA) and lipid
hydroperoxides (LHP) have been described in detail in a
previous article [22]. For information only: i) plasma con-
centrations of vitamin A, vitamin E, lutein, and beta-carotene
were determined by high-performance liquid chromatogra-
phy with a diode array detection [23]; ii) MDA was deriva-
tized with a new highly specific reagent (diaminonaphtalene)
and quantified by HPLC-UV chromatography [24]; iii) LHP
were measured using an automatic method [25] derived from
that originally published by Jiang and reevaluated by
Nourooz-Zadeh [26]. Reduced glutathione (GSH) in whole
blood was assessed by LC/MS, after thiol-derivatization with
N ethyl maleimide as described recently [27].
2.2.5. Urinary markers of lipid peroxidation
Specific urinary markers of lipid peroxidation issued from
n-3 and n-6 fatty acids recently characterized [28] were
measured: 4-hydroxy-2E-nonenoic acid (4-HNA) represent-
ing all n-6 fatty acids, 4-hydroxy-2E-hexenoic acid (4-HHA)
deriving from n-3 fatty acids and 4-hydroxy-2E-dodecadie-
noic acid (4-HDDA) as an index of 12-lipoxygenation of
arachidonic acid. Urine was collected between 8 p.m. and
8 a.m. Samples were frozen and stored at −80 °C until
analysis. Each analysis was repeated four times. Urinary
samples (5 mL) were spiked with 20 ng of CD3 internal
standards (4-HHA-d3, 4-HNA-d3 and 4-HDDA-d3), acidi-
fied to pH 3 using 3 M hydrochloric acid and extracted twice
by 15 mL of ethyl acetate. The organic phase was removed
Table 2
Variations of weight before and after Omegavenous infusions
Weight before Weight after
Child 1 24.5 26
Child 2 22.2 23.5
Child 3 27.3 27.8
Child 4 27.2 27.6
Child 5 28.5 29.8
Child 6 52.2 50.8
Adult 1 62.7 60.2
Adult 2 45.0 45.6
Adult 3 48.0 48.2
Adult 4 56.0 55.2
Adult 5 45.0 45.0
Adult 6 50.0 48.9
Adult 7 53.5 52.6
Fig. 1. Platelet fatty acid composition. Variation for EPA and DHA,
expressed in molar percentage, before and after Omegavenous infusions
(box-plots with median, and individual values).
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dichloromethane and applied to a Sep-Pak silica cartridge.
Hydroxy acids were eluted with hexane/diethylether/acetic
acid (50:50:1, v/v) and transferred into conical vials for their
further derivatization.
2.2.5.1. Gas chromatography-mass spectrometry derivati-
zation of 4-hydroxy-acids. The organic solvent was
removed under nitrogen and the sample was dissolved into
60 μL of acetonitrile, after which 20 μL of 350 g/L α-
bromo-2,3,4,5,6-pentafluorotoluene in acetonitrile and
20 μL of N-ethyldiisopropylamine were added, and the
mixture was heated at 40 °C for 30min. The pentafluorobenzyl
(PFB) ester derivatives were then evaporated to dryness under
nitrogen. The residues were dissolved with 500 μL of toluol
and treated with 50 μL HFBI for 15 min at 60 °C. One mL of
toluol was added, and samples were washed with water (2 mL
of the organic layer was removed and evaporated under
nitrogen). Residues were dissolved into hexane (100 μL). One
microliter aliquot of pentafluorobenzyl heptafluorobutyryl
ester derivatives was analyzed by GC-MS in the splitless
mode. Signals at m/z 325, 367, 407, 328, 370 and 410
corresponding to 4-HHA, 4-HNA and 4-HDDA and their CD3
analogues, respectively, were recorded.
2.2.6. Other laboratory tests
They included routine assays for total leucocytes and
polymorphonuclear cells, C-reactive protein, liver function
tests, creatininemia, and coagulation parameters.
3. Data analysis
The main outcomes were to evaluate the effect of n-3 FA
administration firstly on platelet and plasma FA composition
and secondly on oxidative status, each patient being its own
control for each parameter measured before and after
treatment.
Statistical analysis was realized with Stata8© (StataCorp,
College Station, TX). Because of the small number ofpatients, data are presented as median (min–max) and a
nonparametric test was used for analysis. Longitudinal data
between the evaluations were compared using the Wilcoxon
signed-rank test (when there were two sequential measure-
ments), or one-way repeated measurement analysis of
variance (when more than two sequential measurements)
with Scheffe post hoc tests when appropriate. The level of
significance was set at 0.05.
4. Results
4.1. Clinical evaluation
No significant variations in height and weight were ob-
served in children. A significant decrease in weight was
observed for the 7 adult patients: their median weight was
50 kg (45–62.7) before infusions and 48.2 kg (45–60.2) after
infusions ( p=0.02). A marked weight loss was individually
noted for four patients (nos. 1, 4, 6 and 7, Table 2). It was not
explained by bronchial exacerbation, digestive disease, re-
duced food intake or uncontrolled diabetes mellitus. Two of
them (nos. 6 and 7) preferred to stop the study after the 4th
and 5th infusions respectively because of the weight loss.
Their second evaluation was underwent one week after their
last infusion. They recovered their initial weight one month
after the last infusion.
We observed no significant modification in pulmonary
function tests (FEV1 and FVC).
4.2. FA composition of platelets
Both EPA and DHA platelet molar percentage increased
significantly: the median (min–max) value of molar per-
centage increased from 0.39 (0.22–0.49) before treatment to
0.54 (0.27–0.59) after treatment for EPA ( p=0.003), and
from 1.18 (0.76–1.71) to 1.49 (1.12–2.33) for DHA ( p=
0.0044) (Fig. 1). These increases were significant for both
children ( p=0.02 for EPA and DHA) and adults ( p=0.02 for
EPA and 0.04 for DHA).
Table 3
Median (min. and max.) values before and after the period of intravenous infusion for cGPx, PHGPx, total MDA and LHP, reduced glutathione
Children Adults
Before treatment After treatment Before treatment After treatment
Platelet cGPx Nmol/min/mg of proteins 285.5 (258–334) 323 (263–434) 296 (191–412) 294 (170–407)
Platelet PHGPx Nmol/min/mg of proteins 4.55 (3.38–6.35) 5 (3.5–5.63) 6.3 (4.2–8.3) 6 (2.7–8)
MDA nmol/L 226 (138–431) 208 (174–476) 261 (160–301) 343 (274–541)
LHP μmol/L 12.4 (9.5–21) 14.5 (12.3–25) 12.2 (2.5–18) 9.5 (3.5–13)
GSH μmol/L 980 (894–1237) 1103 (804–1459) 1323 (967–1451) 1206 (1042–1588)
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decrease in n-9 percentage ( p=0.05).
4.3. Plasma FA composition
We observed no significant change in plasma cholesteryl
ester (CE) and phospholipid (PL) FA profiles for n-3, n-6, n-
7 and n-9, neither in children nor in adult patients. A slight
but non significant increase in plasmatic PL EPA and DHA
was observed: PL EPA 0.9% (0.6–1.1) before treatment and
1.1 (0.7–1.4) after treatment; PL DHA 2.2 (0.9–4.3) before
and 2.5 (1.9–4.5) after.
4.4. Markers of oxidative stress
4.4.1. Platelet glutathione peroxidase activities
Cytosolic and phospholipid GPx (cGPx and PHGPx)
activities were not modified by lipid infusions, either for
adults or for children (Table 3).
4.4.2. Plasma LHP and MDA
Total MDA was measured before and after the twelve
weeks of infusion and, in all patients, 4 h after the first
infusion to avoid early oxidative reaction. No significant
modification was observed after the first infusion and no
modification after the end of treatment (Table 3).
The basal values for LHP were elevated compared with
usual values measured in healthy controls (4.9±1.7 μmol/L)
[25]. However we did not observe any significant variation
after the period of treatment (Table 3).
4.4.3. Urinary markers of lipid peroxidation
Significantly elevated values of HHA, HNA and HDDA
were observed for CF patients (mean±SD: 4-HHA 147±32,
4-HNA 72.4±20.7, 4-HDDA 14.2±3.2 pg/μmol creatinine –
compared with values of controls previously studied – 75.4±Table 4
Variations of reduced glutathione (μmol/L) before and after Omegavenous
infusions in the four patients undergoing weight loss
Weight before Weight after rGSH before rGSH after
Adult 1 62,7 60,2 1224 1042
Adult 4 56.0 55.2 1432 1206
Adult 6 50.0 48.9 1451 1123
Adult 7 53.5 52.6 1323 113620.4, 7.2±1.9, 1.4±0.4 respectively) [28]. These markers
were not modified by Omegavenous® administration.
4.4.4. Vitamin A and E, β-carotene, glutathione
We observed no significant variation in vitamin A and E
concentrations, and no significant variation in reduced GSH
(Table 3). However a marked decrease in GSH level was
noted in the four adult patients who developed unexplained
weight loss (nos. 1, 4, 6, and 7, Table 4).
4.5. Miscellaneous
There was no modification in sweat chloride concentra-
tions (data not shown).
There were no significant variations for the other
biological parameters including total leucocytes, C-reactive
protein, liver function tests, creatininemia and coagulation
test (data not shown).
5. Discussion
This preliminary study shows that 3 months of weekly
intravenous administration of n-3 enriched FA emulsion led
to a significant incorporation of EPA and DHA in platelet FA
as previously demonstrated with long-term oral supplemen-
tation on erythrocyte FA composition [9,11]. It would be
interesting to check the modifications observed in FA
membrane.
We observed slight but no significant variations in plasma
FA concentrations, in contrast to another study which
described an increase in n-3 plasma FA concentrations
[10]. This study concerned daily intravenous administration
during one month. In our study, a weekly administration may
suppose a rapid incorporation of circulating n-3 in cell
membrane phospholipids, particularly for EPA and DHA
which represent a very low percentage of total FA
composition; the daily monitoring of plasma composition
after infusion may allow to observe the kinetic of plasma
changes.
Some major circulating markers of oxidative stress, such
as MDA, LHP and specific urinary markers of lipid
hydroperoxides, have been measured either normal or ele-
vated in previous studies in cystic fibrosis patients [22,28];
n-3 long chain FA administration in the present report did not
induce either increase or decrease of these markers. We
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major antioxidant parameter, reduced glutathione, for four
adult patients who also presented a significant weight loss,
suggesting potential oxidative stress, while vitamins such as
vitamin A and E, for which patients have regular supple-
mentation, were not modified. It is known that GSH
scavenges free radicals and lipoperoxidation by-products
directly and indirectly through enzymatic reactions during
which glutathione is oxidized to glutathione disulfide
(GSSG). GSSG is quickly reduced to glutathione by
NADPH-dependant glutathione reductase in order to main-
tain a normal reduced-to-oxidized glutathione ratio and a
very low level of circulating GSSG [29]. The decrease in
total and reduced glutathione could be interpreted as a sign of
insufficient induction of GSH synthesis normally observed
during oxidative stress.
No clinical benefit concerning respiratory function was
observed. This uncontrolled study with a small number of
patients was not planned in order to document a clinical
effect, which needs a randomized control trial.
The reversible weight loss observed in some adult
patients is difficult to understand. We noted no complication
related to CF disease (bronchial exacerbations, uncontrolled
diabetes mellitus) or any reduction in food intake related to
weekly FA administration. The weight loss and the decrease
in reduced GSH concerned the same patients, but our data do
not support a direct link between weight loss and oxidative
stress.
It has been suggested that DHA can have different effects
on cell function and susceptibility to oxidative damage
depending on its phospholipid accumulation in phosphati-
dylcholine or phosphatidylethanolamine plasmalogens
which differs according to DHA concentration [16]. This
results in a biphasic effect of DHA with antioxidant and
prooxidant effects at low and high concentrations [16,30,31].
We observed no direct signs of oxidative stress or lipid
peroxidation induced by treatment either in plasma or in
platelets. However some clinical and biological results ob-
served in adult patients suggest that specific fatty acid treat-
ment should be approached with great caution in cystic
fibrosis [32]; careful attention should be claimed to deter-
mine the dose effect of DHA on redox status in the specific
condition of CF patients.
The beneficial effect of DHA administration in CF
patients remains to be demonstrated. A better understanding
of FA metabolism and the dose effect of DHA on redox
status in CF patients is necessary before clinical trials can be
undertaken.
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